The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND.Newer systemic therapies have significantly advanced the treatment of multiple myeloma, but additional agents are needed. Bortezomib is a proteasome inhibitor with efficacy in relapsed/refractory multiple myeloma that inhibits tumor angiogenesis, a process that has been implicated in multiple myeloma pathogenesis.
METHODS.In AMBER(“A Randomized, Blinded, Placebo‐Controlled, Multicenter,...
BACKGROUND:Vascular endothelial growth factor is up‐regulated in hepatocellular carcinoma (HCC) and is further up‐regulated after transhepatic arterial chemoembolization. The authors of this report conducted a phase 2 trial to evaluate the safety and efficacy of bevacizumab combined with chemoembolization in patients with unresectable HCC.
METHODS:Patients who had an Eastern Cooperative Oncology...
BACKGROUNDA previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S‐1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first‐line treatment for advanced non–small cell lung cancer (NSCLC). In the current study, the authors evaluated the efficacy and safety of combined S‐1, carboplatin, and bevacizumab followed by...
BACKGROUNDIn this multicenter, open‐label, randomized phase 2 trial, the authors evaluated the vascular endothelial growth factor receptor inhibitor axitinib, bevacizumab, or both in combination with chemotherapy as first‐line treatment of metastatic colorectal cancer (mCRC).
METHODSPatients with previously untreated mCRC were randomized 1:1:1 to receive continuous axitinib 5 mg twice daily, bevacizumab...
BACKGROUNDBevacizumab received US Food and Drug Administration approval for use in recurrent glioblastoma based on promising radiographic response data, but without clear evidence that it prolongs survival. A population‐based analysis was conducted to determine whether bevacizumab approval was associated with improved glioblastoma survival in the United States.
METHODSSurveillance, Epidemiology,...
BACKGROUNDDespite a high radiographic response rate in patients with recurrent glioblastoma following bevacizumab therapy, survival benefit has been relatively modest. We assess whether tumor volume measurements based on baseline and early posttreatment MRI can stratify patients in terms of progression‐free survival (PFS) and overall survival (OS).
METHODSBaseline (−4 +/‐ 4 days) and posttreatment...
BACKGROUNDThe objective of this study was to evaluate the comparative effectiveness of strategies that incorporated bevacizumab into the primary platinum‐based treatment of ovarian cancer: 1) no bevacizumab; 2) concurrent and maintenance bevacizumab for all; 3) bevacizumab for suboptimally debulked stage III and stage IV disease (high‐risk cohort); and the evaluation of an alternative exploratory...
BACKGROUNDThe incidence and spectrum of acute toxicities related to the use of bevacizumab (BVZ)‐containing regimens in children are largely unknown. This report describes the adverse events in a recently completed large phase 2 trial of BVZ plus irinotecan (CPT‐11) in children with recurrent central nervous system tumors.
METHODSPediatric Brain Tumor Consortium trial‐022 evaluated the efficacy and...
BACKGROUNDIn patients with previously untreated metastatic colorectal cancer (mCRC), we conducted a phase 1b/randomized phase 2 trial to define the safety, tolerability, and efficacy of mFOLFOX6 plus bevacizumab (mFOLFOX6/bev) with conatumumab, an investigational, fully human monoclonal IgG1 antibody that specifically activates death receptor 5 (DR5).
METHODSTwelve patients were enrolled in a phase...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.